pathologic neovascularization

Summary

Summary: A pathologic process consisting in proliferation of blood vessels in abnormal tissues or in abnormal positions.

Top Publications

  1. ncbi The hallmarks of cancer
    D Hanahan
    Department of Biochemistry, Hormone Research Institute, University of California at San Francisco, 94143, USA
    Cell 100:57-70. 2000
  2. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
  3. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
  4. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  5. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
  6. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
  7. doi Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  8. ncbi Angiogenesis in life, disease and medicine
    Peter Carmeliet
    Center of Transgene Technology and Gene Therapy, University of Leuven, Flanders Interuniversity Institute for Biotechnology VIB, B 3000 Leuven, Belgium
    Nature 438:932-6. 2005
  9. ncbi Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
  10. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005

Detail Information

Publications288 found, 100 shown here

  1. ncbi The hallmarks of cancer
    D Hanahan
    Department of Biochemistry, Hormone Research Institute, University of California at San Francisco, 94143, USA
    Cell 100:57-70. 2000
  2. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  3. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  4. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  5. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
    ....
  6. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
    ....
  7. doi Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  8. ncbi Angiogenesis in life, disease and medicine
    Peter Carmeliet
    Center of Transgene Technology and Gene Therapy, University of Leuven, Flanders Interuniversity Institute for Biotechnology VIB, B 3000 Leuven, Belgium
    Nature 438:932-6. 2005
    ..Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments...
  9. ncbi Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
    ....
  10. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005
    ..Our findings indicate that fibroblasts within invasive breast carcinomas contribute to tumor promotion in large part through the secretion of SDF-1...
  11. ncbi Mechanisms of angiogenesis and arteriogenesis
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy Flanders Interuniversity Institute for Biotechnology KU Leuven, Leuven, B 3000, Belgium
    Nat Med 6:389-95. 2000
    ....
  12. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
    ....
  13. ncbi Tumorigenesis and the angiogenic switch
    Gabriele Bergers
    University of California San Francisco, Department of Neurological Surgery, Brain Tumor Research Center and Comprehensive Cancer Center, HSE 722, 513 Parnassus Avenue, San Francisco, California 94143 0520, USA
    Nat Rev Cancer 3:401-10. 2003
    ....
  14. ncbi Angiogenesis in health and disease
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KULeuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Med 9:653-60. 2003
    ..Molecular insights into these processes are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated...
  15. ncbi Regulation of angiogenesis by hypoxia: role of the HIF system
    Christopher W Pugh
    The Henry Wellcome Building of Genomic Medicine, Roosevelt Drive, Oxford, OX3 7BN, UK
    Nat Med 9:677-84. 2003
    ..We also discuss the implications of oncogenic activation of extensive, physiologically interconnected hypoxia pathways for the tumor phenotype...
  16. ncbi Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Daniel J Hicklin
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
    J Clin Oncol 23:1011-27. 2005
    ....
  17. pmc Modes of resistance to anti-angiogenic therapy
    Gabriele Bergers
    University of California, San Francisco, Department of Neurological Surgery, Brain Tumour Research Center, San Francisco, California 94143, USA
    Nat Rev Cancer 8:592-603. 2008
    ....
  18. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
    ..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...
  19. pmc Inflammation and cancer
    Lisa M Coussens
    Cancer Research Institute, Department of Pathology, University of California, San Francisco, California 94143, USA
    Nature 420:860-7. 2002
    ..These insights are fostering new anti-inflammatory therapeutic approaches to cancer development...
  20. ncbi Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    Oriol Casanovas
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 8:299-309. 2005
    ..These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition...
  21. ncbi Distinct role of macrophages in different tumor microenvironments
    Claire E Lewis
    Academic Unit of Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, United Kingdom
    Cancer Res 66:605-12. 2006
    ..This review will discuss the evidence for differential regulation of TAMs in these microenvironments and provide an overview of current attempts to target or use TAMs for therapeutic purposes...
  22. ncbi Vascular endothelial growth factor: basic science and clinical progress
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Endocr Rev 25:581-611. 2004
    ..Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration...
  23. ncbi Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
    T Asahara
    Department of Medicine, St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Circ Res 85:221-8. 1999
    ....
  24. ncbi The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
    P H Maxwell
    Wellcome Trust Centre for Human Genetics, Oxford, UK
    Nature 399:271-5. 1999
    ..Thus, constitutive HIF-1 activation may underlie the angiogenic phenotype of VHL-associated tumours. The pVHL/HIF-1 interaction provides a new focus for understanding cellular oxygen sensing...
  25. ncbi Molecular regulation of vessel maturation
    Rakesh K Jain
    E L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Med 9:685-93. 2003
    ..Normalization of the abnormal vasculature can facilitate drug delivery to tumors and formation of a mature vasculature can help realize the promise of therapeutic angiogenesis and tissue engineering...
  26. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  27. ncbi Role of angiogenesis in tumor growth and metastasis
    Judah Folkman
    Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA, USA
    Semin Oncol 29:15-8. 2002
    ..Phase 1 clinical trials of endostatin and angiostatin are ongoing, and preliminary results show minimal toxicities...
  28. ncbi Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
    Michele De Palma
    Angiogenesis and Tumor Targeting Research Unit, San Raffaele Institute, Milano, Italy
    Cancer Cell 8:211-26. 2005
    ..Therefore, Tie2 expression characterizes three distinct cell types required for tumor neovascularization: ECs, proangiogenic cells of hematopoietic origin, and pericyte precursors of mesenchymal origin...
  29. ncbi Requirement of vascular integrin alpha v beta 3 for angiogenesis
    P C Brooks
    Department of Immunology, Scripps Research Institute, La Jolla, CA 92037
    Science 264:569-71. 1994
    ..These findings suggest that alpha v beta 3 may be a useful therapeutic target for diseases characterized by neovascularization...
  30. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
    ..It may also become an important target for cancer therapy...
  31. ncbi VEGF and the quest for tumour angiogenesis factors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Cancer 2:795-803. 2002
    ..How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumour progression...
  32. ncbi Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, Belgium
    Nat Med 7:575-83. 2001
    ..By upregulating PlGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders...
  33. ncbi Angiogenesis
    Judah Folkman
    Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115 5737, USA
    Annu Rev Med 57:1-18. 2006
    ..Several types of angiogenesis inhibitors reveal a biphasic, U-shaped curve of efficacy. "Antiangiogenic chemotherapy" is a novel approach to the treatment of drug resistance...
  34. ncbi Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
    Ricky T Tong
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 64:3731-6. 2004
    ..Thus, vascular normalization may contribute to the improved survival rates in tumor-bearing animals and in colorectal carcinoma patients treated with an anti-VEGF antibody in combination with cytotoxic therapies...
  35. ncbi Macrophages regulate the angiogenic switch in a mouse model of breast cancer
    Elaine Y Lin
    Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 66:11238-46. 2006
    ..Taken together, this study shows that tumor-associated macrophages play a key role in promoting tumor angiogenesis, an essential step in the tumor progression to malignancy...
  36. ncbi Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
    Irene Noguera-Troise
    Regeneron Research Laboratories, 777 Old Saw Mill River Road, Tarrytown, New York 10591, USA
    Nature 444:1032-7. 2006
    ....
  37. pmc Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
    R Ravi
    Johns Hopkins Oncology Center, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 USA
    Genes Dev 14:34-44. 2000
    ..These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis...
  38. ncbi Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    D Lyden
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Nat Med 7:1194-201. 2001
    ..These data demonstrate that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggest new clinical strategies to block tumor growth...
  39. ncbi VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
    S A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Nat Med 7:186-91. 2001
    ..This study demonstrates that lymphatics can be established in solid tumors and implicates VEGF family members in determining the route of metastatic spread...
  40. ncbi Angiogenesis in brain tumours
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Rev Neurosci 8:610-22. 2007
    ..This creates a window of opportunity for optimally combining chemotherapeutics and radiation...
  41. ncbi Basement membranes: structure, assembly and role in tumour angiogenesis
    Raghu Kalluri
    Center for Matrix Biology, Department of Medicine, Dana 514, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 3:422-33. 2003
    ..Vascular BM components have recently been found to be involved in the regulation of tumour angiogenesis, making them attractive candidate targets for potential cancer therapies...
  42. pmc An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
    Enrico Giraudo
    Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
    J Clin Invest 114:623-33. 2004
    ....
  43. ncbi Angiogenesis as a therapeutic target
    Napoleone Ferrara
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 438:967-74. 2005
    ..Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first...
  44. ncbi Tumor response to radiotherapy regulated by endothelial cell apoptosis
    Monica Garcia-Barros
    Laboratory of Signal Transduction, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Science 300:1155-9. 2003
    ..These studies indicate that microvascular damage regulates tumor cell response to radiation at the clinically relevant dose range...
  45. ncbi Clinical translation of angiogenesis inhibitors
    Robert Kerbel
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, S 218, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 2:727-39. 2002
    ..What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?..
  46. ncbi Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
    Li Yang
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Cancer Cell 6:409-21. 2004
    ..Our data provide evidence that Gr+CD11b+ cells of immune origin induced by tumors directly contribute to tumor growth and vascularization by producing MMP9 and differentiating into ECs...
  47. ncbi VEGF as a key mediator of angiogenesis in cancer
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flander s Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Oncology 69:4-10. 2005
    ..These characteristics mean that tumor blood flow is suboptimal, resulting in hypoxia and further VEGF production. This central role of VEGF in the production of tumor vasculature makes it a rational target for anticancer therapy...
  48. ncbi Role of tumor-associated macrophages in tumor progression and invasion
    Alberto Mantovani
    Istituto Clinico Humanitas, 20089 Rozzano, Milan, Italy
    Cancer Metastasis Rev 25:315-22. 2006
    ..Here, we discuss evidence supporting the view that TAM represent a unique and distinct M2-skewed myeloid population and a potential target of anti-cancer therapy...
  49. ncbi Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
    John Ridgway
    Tumor Biology and Angiogenesis, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 444:1083-7. 2006
    ..Therefore, targeting Dll4 might represent a broadly efficacious and well-tolerated approach for the treatment of solid tumours...
  50. ncbi Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
    Guilian Niu
    Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Department of Oncology, University of South Florida College of Medicine, Tampa, Florida, FL 33612, USA
    Oncogene 21:2000-8. 2002
    ..These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers...
  51. ncbi Retinal angiogenesis in development and disease
    Ray F Gariano
    Department of Ophthalmology, A 157, 300 Pasteur Drive, Stanford University School of Medicine, Palo Alto, California 94305, USA
    Nature 438:960-6. 2005
    ..The retina and its clinical disorders have a pivotal role in angiogenesis research and provide model systems in which to investigate neurovascular relationships and angiogenic diseases...
  52. ncbi Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us
    Lynn Hlatky
    Dana Farber Cancer Institute and the Department of Radiation Oncology, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 94:883-93. 2002
  53. ncbi Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
    M Skobe
    Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
    Nat Med 7:192-8. 2001
    ..These results establish the occurrence and biological significance of intratumoral lymphangiogenesis in breast cancer and identify VEGF-C as a molecular link between tumor lymphangiogenesis and metastasis...
  54. ncbi The role of myeloid cells in the promotion of tumour angiogenesis
    Craig Murdoch
    Department of Oral and Maxillofacial Surgery, School of Clinical Dentistry, Beech Hill Road, University of Sheffield, Sheffield, UK
    Nat Rev Cancer 8:618-31. 2008
    ..We also discuss the therapeutic implications of recent findings that specific myeloid cell populations modulate the responses of tumours to agents such as chemotherapy and some anti-angiogenic therapies...
  55. pmc Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
    L M Coussens
    Hormone Research Institute, University of California, San Francisco San Francisco, California 94143 0534, USA
    Genes Dev 13:1382-97. 1999
    ....
  56. pmc Rapid vascular regrowth in tumors after reversal of VEGF inhibition
    Michael R Mancuso
    Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy, UCSF, San Francisco, California 94143 0452, USA
    J Clin Invest 116:2610-21. 2006
    ....
  57. pmc Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors
    Shunichi Morikawa
    Department of Anatomy and Cardiovascular Research Institute and Comprehensive Cancer Center, University of California, San Francisco, California 94143 0130, USA
    Am J Pathol 160:985-1000. 2002
    ..The association of pericytes with endothelial sprouts raises the possibility of an involvement in sprout growth or retraction in tumors...
  58. ncbi Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
    Marco Presta
    Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy
    Cytokine Growth Factor Rev 16:159-78. 2005
    ..Indeed, several experimental evidences point to a role for FGFs in tumor growth and angiogenesis. This review will focus on the relevance of the FGF/FGF receptor system in adult angiogenesis and its contribution to tumor vascularization...
  59. ncbi Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
    Farbod Shojaei
    Genentech, Inc, 1 DNA Way, S San Francisco, California 94080, USA
    Nat Biotechnol 25:911-20. 2007
    ..These findings indicate that, in our models, refractoriness to anti-VEGF treatment is determined by the ability of tumors to prime and recruit CD11b+Gr1+ cells...
  60. ncbi Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 394:485-90. 1998
    ..As hypoxic stress contributes to many (patho)biological disorders, this new role for HIF-1alpha in hypoxic control of cell growth and death may be of general pathophysiological importance...
  61. ncbi The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions
    Hiroyuki Takahashi
    Division of Genetics, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokane dai, Minato ku, Tokyo, 108 8639, Japan
    Clin Sci (Lond) 109:227-41. 2005
    ..Recent progress in the molecular and biological understanding of the VEGF/VEGFR system provides us with novel and promising therapeutic strategies and target proteins for overcoming a variety of diseases...
  62. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  63. ncbi SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
    T A Fong
    SUGEN, Inc, South San Francisco, California 94080, USA
    Cancer Res 59:99-106. 1999
    ..These findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types...
  64. pmc Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Breast Cancer Res 2:252-7. 2000
    ..Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours..
  65. ncbi Interleukin-8 as a macrophage-derived mediator of angiogenesis
    A E Koch
    Department of Medicine, Northwestern University Medical School, Chicago, IL 60611
    Science 258:1798-801. 1992
    ..These data suggest a function for macrophage-derived IL-8 in angiogenesis-dependent disorders such as rheumatoid arthritis, tumor growth, and wound repair...
  66. ncbi Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
    Dana D Hu-Lowe
    Department of Cancer Biology, PGRD La Jolla, Pfizer, Inc, San Diego, California 92121, USA
    Clin Cancer Res 14:7272-83. 2008
    ..We provide a comprehensive description of its in vitro characteristics and activities, in vivo antiangiogenesis, and antitumor efficacy and translational pharmacology data...
  67. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
    ..Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  68. ncbi Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth
    Qi Pan
    Tumor Biology and Angiogenesis, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Cell 11:53-67. 2007
    ..We propose that blocking NRP1 function inhibits vascular remodeling, rendering vessels more susceptible to anti-VEGF therapy...
  69. ncbi Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action
    Judah Folkman
    Children s Hospital Harvard Medical School, Cambridge, MA, USA
    Exp Cell Res 312:594-607. 2006
    ....
  70. pmc MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
    Peter Olson
    Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 23:2152-65. 2009
    ..Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality...
  71. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999
    ..Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued...
  72. ncbi Tumor angiogenesis: past, present and the near future
    R S Kerbel
    Sunnybrook and Women s College Health Sciences Centre, Division of Cancer Biology Research, S 218 Research Building, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Carcinogenesis 21:505-15. 2000
    ..Also of concern is that the expected need to use anti-angiogenic drugs chronically will lead to delayed toxic side effects in humans, which do not appear in rodents, especially in short-term studies...
  73. ncbi The anti-angiogenic basis of metronomic chemotherapy
    Robert S Kerbel
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 4:423-36. 2004
  74. ncbi JunD reduces tumor angiogenesis by protecting cells from oxidative stress
    Damien Gerald
    Unit of Gene Expression and Diseases, CNRS URA 1644, Pasteur Institute, 25 rue du Docteur Roux, 75724 Paris, Cedex 15, France
    Cell 118:781-94. 2004
    ..Furthermore, we provide new insights into the regulation of PHD activity, allowing immediate reactive adaptation to changes in O2 or iron levels in the cell...
  75. pmc Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
    J L Rubenstein
    Division of Hematology Oncology, University of California, San Francisco, USA
    Neoplasia 2:306-14. 2000
    ....
  76. pmc Origin of endothelial progenitors in human postnatal bone marrow
    Morayma Reyes
    Stem Cell Institute, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Clin Invest 109:337-46. 2002
    ..Because MAPCs can be expanded in culture without obvious senescence for more than 80 population doublings, they may be an important source of endothelial cells for cellular pro- or anti-angiogenic therapies...
  77. ncbi Vascular endothelial growth factor is a secreted angiogenic mitogen
    D W Leung
    Department of Molecular Biology, Genetech, South San Francisco, CA 94080
    Science 246:1306-9. 1989
    ..Human 293 cells transfected with an expression vector containing a bovine or human VEGF cDNA insert secrete an endothelial cell mitogen that behaves like native VEGF...
  78. ncbi Hypoxia signalling in cancer and approaches to enforce tumour regression
    Jacques Pouyssegur
    Institute of Signalling, Developmental Biology and Cancer Research, CNRS UMR 6543, University of Nice, Centre Antoine Lacassagne, 33 Avenue Valombrose, 06189 Nice, France
    Nature 441:437-43. 2006
    ..There are new approaches to enforce necrotic cell death and tumour regression by targeting tumour metabolism and pH(i)-control systems...
  79. pmc Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin
    Yuki Hamano
    Center for Matrix Biology, Department of Medicine and Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Cancer Cell 3:589-601. 2003
    ..These results indicate that MMP-generated fragments of basement membrane collagen can have endogenous function as integrin-mediated suppressors of pathologic angiogenesis and tumor growth...
  80. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  81. ncbi Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
    M S Pepper
    Department of Morphology, University Medical Center, Geneva, Switzerland
    Arterioscler Thromb Vasc Biol 21:1104-17. 2001
    ..Antiproteolysis, particularly in the context of angiogenesis, has become a key target in therapeutic strategies aimed at inhibiting tumor growth and other diseases associated with neovascularization...
  82. pmc Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
    Dawid G Nowak
    Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK
    J Cell Sci 121:3487-95. 2008
    ....
  83. ncbi Vascular endothelial growth factor signaling pathways: therapeutic perspective
    Marcin Kowanetz
    Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 12:5018-22. 2006
    ..Aberrant VEGF signaling is also a feature of several other pathologic conditions, such as age-related macular degeneration and rheumatoid arthritis...
  84. pmc Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization
    Daniel J Nolan
    Cancer Genome Research Center, Cold Spring Harbor Laboratory, Woodbury, New York 11797, USA
    Genes Dev 21:1546-58. 2007
    ..Our results demonstrate that BM-derived EPCs are critical components of the earliest phases of tumor neoangiogenesis...
  85. pmc Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
    Mark W Dewhirst
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Rev Cancer 8:425-37. 2008
    ..HIF1 can then promote endothelial and tumour cell survival. As discussed here, a constant theme emerges: inhibition of HIF1 activity will have therapeutic benefit...
  86. ncbi 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
    Nicola J Mabjeesh
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Cell 3:363-75. 2003
    ..These data establish 2ME2 as a small molecule inhibitor of HIF-1 and provide a mechanistic link between the disruption of the MT cytoskeleton and inhibition of angiogenesis...
  87. ncbi Matrix metalloproteinases and angiogenesis
    Joyce E Rundhaug
    Department of Carcinogenesis, Science Park Research Division, The University of Texas M D Anderson Cancer Center, Smithville, TX, 78957, USA
    J Cell Mol Med 9:267-85. 2005
    ..However, because of the multiple effects of MMPs on angiogenesis, careful testing of these MMP inhibitors is necessary to show that these compounds do not actually enhance angiogenesis...
  88. ncbi Fibroblasts in cancer
    Raghu Kalluri
    Center for Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 6:392-401. 2006
    ..Fibroblasts are therefore a key determinant in the malignant progression of cancer and represent an important target for cancer therapies...
  89. ncbi Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells
    Noriyuki Ouchi
    Molecular Cardiology Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 279:1304-9. 2004
    ..These data indicate that adiponectin can function to stimulate the new blood vessel growth by promoting cross-talk between AMP-activated protein kinase and Akt signaling within endothelial cells...
  90. ncbi Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch
    George N Naumov
    Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    Cell Cycle 5:1779-87. 2006
    ....
  91. ncbi Bone marrow-derived cells do not incorporate into the adult growing vasculature
    Tibor Ziegelhoeffer
    Max Planck Institute for Clinical and Physiological Research, Bad Nauheim, Germany
    Circ Res 94:230-8. 2004
    ..Our findings suggest that in the adult organism, bone marrow-Derived cells do not promote vascular growth by incorporating into vessel walls but may function as supporting cells...
  92. ncbi Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
    T Itoh
    Shionogi Institute for Medical Science, Shionogi and Co, Ltd, Osaka, Japan
    Cancer Res 58:1048-51. 1998
    ..014 and P < 0.0015, respectively). These results indicated that host-derived gelatinase A plays an important role in angiogenesis and tumor progression, suggesting the usefulness of gelatinase A inhibitors for anticancer chemotherapy...
  93. pmc Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors
    Sunyoung Lee
    Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles 90095, USA
    J Cell Biol 169:681-91. 2005
    ..Our findings support the view that matrix-bound VEGF and nontethered VEGF provide different signaling outcomes. These findings reveal a novel aspect in the regulation of extracellular VEGF that holds significance for vascular patterning...
  94. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  95. pmc Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications
    Balazs Dome
    Department of Tumor Biology and Thoracic Oncology, National Koranyi Institute of Pulmonology, Budapest, Hungary
    Am J Pathol 170:1-15. 2007
    ..This review intends to integrate our recent knowledge in this field into a rational strategy that could be the basis for developing effective clinical modalities using antivascular therapy for cancer...
  96. ncbi The hypoxic response of tumors is dependent on their microenvironment
    Barbara Blouw
    Molecular Biology Section, Division of Biological Sciences, University of California at San Diego, Pacific Hall Room 1212, MC 0366, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Cancer Cell 4:133-46. 2003
    ..These results demonstrate that HIF-1alpha has differential roles in tumor progression, which are greatly dependent on the extant microenvironment of the tumor...
  97. ncbi Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis
    Nan Tang
    Molecular Biology Section, Division of Biological Sciences, University of California, San Diego, San Diego, California 92093, USA
    Cancer Cell 6:485-95. 2004
    ..We thus show that a HIF-1alpha-driven, VEGF-mediated autocrine loop in EC is an essential component of solid tumor angiogenesis...
  98. ncbi Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
    K M Dameron
    Department of Microbiology Immunology, Northwestern University Medical School, Chicago, IL 60611
    Science 265:1582-4. 1994
    ..These data indicate that, in fibroblasts, wild-type p53 inhibits angiogenesis through regulation of TSP-1 synthesis...
  99. ncbi Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo
    Kathleen M Leahy
    Pharmacia, Mail Zone AA4C, 700 Chesterfield Parkway, Chesterfield, Missouri 63017, USA
    Cancer Res 62:625-31. 2002
    ..2-3.0-fold) in response to celecoxib. Thus, the antitumor activity of celecoxib may be attributable, at least in part, to a direct effect on host stromal elements, such as the angiogenic vasculature...
  100. ncbi Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize
    Dai Fukumura
    Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Cell Biochem 101:937-49. 2007
    ..Combined anti-angiogenic and conventional therapies have shown promise in the clinic...
  101. ncbi Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Robert S Kerbel
    Sunnybrook Health Sciences Centre, Departments of Medical Biophysics and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Science 312:1171-5. 2006
    ..I then discuss how these potential mechanisms might be exploited to maximize therapeutic efficacy...

Research Grants68

  1. Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants
    JAMES FRANCIS MCGINNIS; Fiscal Year: 2013
    ..antioxidant activity and long term retention in the retina, will continuously scavenge ROS and inhibit pathologic neovascularization over prolonged times -up to 12 months...
  2. Histone Chaperones in Angiogenesis
    Soumen Paul; Fiscal Year: 2012
    ....
  3. Cyr61/CCN1-Induced Angiogenesis and Vasculogenesis in the Retina
    Brahim Chaqour; Fiscal Year: 2010
    ....
  4. ANGIOTENSIN II SIGNAL TRANSDUCTION
    Bradford C Berk; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: The healing of tissues after surgery or trauma is critical for long-term survival. The proposed work will study novel mechanisms by which blood vessels grow in response to tissue injury. ..
  5. Sphingosine 1-phosphate receptors in vascular homeostasis and pathology
    TIMOTHY TUN HLA; Fiscal Year: 2012
    ..These studies are expected to derive critical insights into the workings of S1P receptors, which are important drug targets to control the vascular and immune systems. ..
  6. Downregulation of Rod Metabolism in Retinopathy of Prematurity
    JAMES DANIEL AKULA; Fiscal Year: 2010
    ..Thus, suppression of metabolically demanding processes in the rods promises preservation of visual function and prevention of vascular disease. ..
  7. Regulation and Function of the Matricellular Protein CCN1 in Ischemic Retinopathy
    Brahim Chaqour; Fiscal Year: 2013
    ..This proposal will provide new insights into the molecular mechanisms of CCN1 activities in vivo and may foster future safer, less destructive, and more effective therapies to harness ischemia-induced neovascularization in ROP. ..
  8. Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis
    Cezary Marcinkiewicz; Fiscal Year: 2012
    ..Investigation of this receptor may be beneficial for cancer as well as for cardiovascular disease having patients, because regulation of vascularization process is important in these pathologies. ..
  9. Role of Protein Kinase D in Skin Epithelia
    Soosan Ghazizadeh; Fiscal Year: 2012
    ....
  10. MATRIX MEDIATORS OF WOUND HEALING
    Paul J Higgins; Fiscal Year: 2010
    ..Our continued clarification of mechanistic controls on PAI-1 gene expression may lead to new targeted therapies for diseases in which excessive or non-resolving angiogenesis is a major pathogenic feature. ..
  11. The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity
    John P Cooke; Fiscal Year: 2013
    ..abstract_text> ..
  12. Role of RPE-derived VEGF in Choroid Development and Stability
    PATRICIA ANN D'AMORE; Fiscal Year: 2013
    ....
  13. Sex-specific Regulation of Acute Inflammation and Resolution
    Karsten Gronert; Fiscal Year: 2013
    ..Hence, results from this study could rapidly bring novel treatment options for ocular surface inflammatory diseases to the clinic. ! ..
  14. Positive Role of MKP-1 in Angiogenesis.
    JOEL BOERCKEL; Fiscal Year: 2013
    ....
  15. Fatty Acid Binding Protein and Pathological Retinal Vascularization
    Magali Saint-Geniez; Fiscal Year: 2012
    ..These studies have the potential to identify FABP4 as a novel therapeutic target in proliferative retinopathies. ..
  16. Anti-angiogenic Barriers to Tumor Development
    Susan E Crawford; Fiscal Year: 2010
    ..This proposed study has the potential to identify a novel signaling pathway in the pathogenesis of liver disease and it may validate PEDF gene therapy as a potent new agent to combat liver cancer. ..
  17. EYA in Retinal Angiogenesis
    Rashmi S Hegde; Fiscal Year: 2013
    ..The EYAs represent a novel and druggable target for treating proliferative retinopathies, and an essential feature of this project is the validation of EYA as a target for anti-angiogenic drug development. ..
  18. INTEGRINS AND OCULAR ANGIOGENESIS
    Martin Friedlander; Fiscal Year: 2013
    ....
  19. Validation and development of specific small molecule inhibitors of HTRA1 for tre
    Shuyuan Yao; Fiscal Year: 2010
    ..Development of specific HTRA1 small molecule inhibitors as described in this SBIR grant application will provide a new therapeutic approach for treating age-related macular degeneration. ..
  20. Universiity of Rochester Center for Medical Countermeasures against Radiation
    JACQUELINE PATRICIA WILLIAMS; Fiscal Year: 2013
    ..SecinH3 has been shown to stabilize the endothelium and inhibit pathologic angiogenesis and vascular leak induced by cytokines and growth factors. SecinH3 will be tested in Projects 1 and 2. ..
  21. Cell-based screening for EphA2 receptor inhibitors
    Elena B Pasquale; Fiscal Year: 2011
    ..Chemical compounds that inhibit EphA2 function will have potential research applications to clarify the role of EphA2 in cancer progression, which is currently not well understood, and therapeutic applications as anti-cancer agents. ..
  22. Regulation of Vascular Morphogenesis in Adult Brain
    Donald R Senger; Fiscal Year: 2010
    ..Thus, new strategies to correct vascular abnormalities in brain are important for improving patient recovery and clinical outcomes. ..
  23. Anti-angiogenesis of HC-HA Covalent Complex and PTX3 Purified from Fetal Membrane
    Scheffer C G Tseng; Fiscal Year: 2011
    ..Consequently, we may develop new therapeutics based on PTX3 bound to HC"HA to treat many diseases in and beyond ophthalmology where unwanted angiogenesis is detrimental to our vision and health. ..
  24. CIB1 regulation of endothelial function
    Leslie V Parise; Fiscal Year: 2013
    ..In this proposal we seek to better understand how endothelial cells, which line all blood vessels, control blood vessel growth, by studying a protein called CIB1, which appears to regulate endothelial cell function. ..
  25. MicroRNAs for therapy of visual disorders
    Martin Friedlander; Fiscal Year: 2013
    ..abstract_text> ..
  26. Regulation of Integrins in Neovasculature Development
    Tatiana V Byzova; Fiscal Year: 2012
    ..abstract_text> ..
  27. Extracellular ATP as regulator of hypoxia-induced vasa vasorum neovascularization
    Evgenia V Gerasimovskaya; Fiscal Year: 2012
    ....
  28. Molecular mechanisms of choroidal neovascularization and vascular homeostasis
    ALEXANDER GEORG MARNEROS; Fiscal Year: 2011
    ..These findings are likely to reveal novel molecular targets for the treatment of neovascular age-related macular degeneration. ..
  29. HIF dysregulation as a novel genetic model to study retinal neovascular disease.
    AKRIT SINGH SODHI; Fiscal Year: 2013
    ..g. ocular tumors and neovascular glaucoma). ..
  30. Caveolin-2 and Endothelial Cell Function
    Grzegorz Sowa; Fiscal Year: 2012
    ..Thus, understanding the molecular mechanisms controlling angiogenesis is of key significance. The knowledge gained from this research will facilitate the treatment of cardiovascular and pulmonary disease, injuries, and cancer. ..
  31. Combination immunotherapies for the treatment of melanoma
    Michael W Fanger; Fiscal Year: 2013
    ....
  32. Role of Egfl7 in Angiogenesis and Vascular Injury
    Heidi Stuhlmann; Fiscal Year: 2013
    ..Understanding how these processes are orchestrated in a living organism may lead to treatments in which endothelial cells aid the repair of damaged vessels or restrict the blood supply of tumors. ..
  33. Complement Inhibitors for Macular Degeneration
    REKHA BANSAL; Fiscal Year: 2013
    ..The demonstration of efficacy and preliminary ocular safety will move this program to an IND stage application. ..
  34. Identification of novel small molecule inhibitors of Arf6 for the treatment of va
    Kirill Ostanin; Fiscal Year: 2013
    ....
  35. Complement Mediated Neovascularization in Retinopathy
    Kip M Connor; Fiscal Year: 2013
    ..Understanding the mechanism by which the complement system mediates neovessel clearance may open new avenues of therapy for ROP and other blinding neovascular ophthalmic diseases. ..
  36. Structural and biophysical characterization of Tie receptor/integrin interactions
    Annamarie C Dalton; Fiscal Year: 2013
    ..Furthermore, structural determination either through x-ray crystallography or cryo-electron microscopy of an Integrin/Tie complex will identify the basis for growth factor receptor-integrin signal transduction. ..
  37. Orphan Nuclear Receptor TR3 in tumor angiogenesis and associated microvessel perm
    Huiyan Zeng; Fiscal Year: 2013
    ..The information from this study will not only enhance our understanding of the pathophyiosiology of tumorigenesis but also help us to develop effective therapeutic approaches for treatment of cancers. ..
  38. Microvascular Permeability and Matrix Fibrinogen Degradation in Trauma
    Mack H Wu; Fiscal Year: 2013
    ..Data derived from this study will provide novel, mechanistic insights into the molecular basis of barrier injury in gastrointestinal microvessels. ..
  39. Alpha6 integrin complexes and tumor progression
    Martin E Hemler; Fiscal Year: 2013
    ..Aim 5 will study, in both tumor and host, the effects of LB integrin complex disruption on metastasis. ..
  40. Downstream of Akt in the tumor vessel
    William C Aird; Fiscal Year: 2012
    ..We anticipate our findings to be relevant not only to the management of tumor progression but to have particular applications in preventing metastasis ..
  41. Regulating retinal microvascular morphogenesis
    Ira M Herman; Fiscal Year: 2010
    ....
  42. miRNA Regulation of Aquaporin 1 Modulates Vascular Remodelling during Cirrhosis
    Robert C Huebert; Fiscal Year: 2013
    ..abstract_text> ..
  43. The Role of Neuroprotectin D1 in Choroidal Neovascularization
    KRISTOPHER GRAYE SHEETS; Fiscal Year: 2012
    ..The outcomes from this study could provide the basis of highly effective low-cost therapies for age-related macular degeneration. ..
  44. Optimization of EphA subtype-selective antagonists as probes for the nervous syst
    Longqin Hu; Fiscal Year: 2010
    ..They could lead to the development of novel therapeutic agents for nervous system disorders including Parkinson's and Alzheimer's disease. ..
  45. Post-biosynthetic remodeling of heparan sulfate
    Joseph Zaia; Fiscal Year: 2013
    ..This research will explore the structure-function relationships of vascular heparan sulfates in order to inform efforts to develop protein binding microarrays, drugs and therapeutics. ..
  46. Investigating the Role of Hypoxia Inducible Factors in Pathological Retinal Angio
    BRYAN LEE KROCK; Fiscal Year: 2012
    ..This study is of great significance to public health because it aims to do these things. ) ..
  47. MicroRNA Regulation Of Cell Survival In Angiogenesis &Vessel Maturation
    Sudarshan Anand; Fiscal Year: 2013
    ..These studies will elucidate how distinct microRNA programs govern the balance between the pro and anti-angiogenic states in the vasculature during development and disease. ..
  48. Notch in Angiogenesis and Vascular Biology
    JAN K KITAJEWSKI; Fiscal Year: 2013
    ..These studies elucidate novel mechanisms of angiogenesis that depend on interactions between endothelial and peri-vascular cells, and may be key to the understanding and treatment of a variety of human vascular pathologies. ..
  49. The role of signaling molecule AIP1 in pathological angiogenesis
    Wang Min; Fiscal Year: 2013
    ..We will test the potential therapeutic effects of AIP1-derived peptides in these models. ..
  50. Mechanisms of ER71/ETV2-regulated Vascularization
    Changwon Park; Fiscal Year: 2013
    ....
  51. Molecular Targeting of Plaque Angiogenesis in Diabetes
    KAREN SIMPSON MOULTON; Fiscal Year: 2012
    ..These molecular targets can be exploited to deliver molecular imaging agents or drugs to the pathologic neovascularization and minimize their effects on normal arteries...
  52. Transcriptional Control of Endothelial Differentiation
    Nathan D Lawson; Fiscal Year: 2013
    ..Finally, we will determine the role of other Ets transcription factors in transducing external signals to drive artery gene expression and morphogenesis. ..
  53. TRAINING PROGRAM IN ANGIOGENESIS AND INFLAMMATION
    HAROLD FISHER DVORAK; Fiscal Year: 2013
    ..D., M.D., or M.D./Ph.D. degrees. The BIDMC and Harvard Medical School have a strong commitment to the recruitment, retention, and encouragement of under-represented minorities, the disabled and individuals from disadvantaged backgrounds. ..
  54. Sphingolipid modulators of vascular growth &homeostasis
    TIMOTHY TUN HLA; Fiscal Year: 2013
    ..Since SIP receptor modulators have entered the therapeutic era, this knowledge is likely to have important clinical utility. ..
  55. Induction of the blood-retinal barrier
    DAVID ANTONETTI; Fiscal Year: 2010
    ..Understanding this mechanism will lead to new therapies to restore the blood-retinal barrier in retinal vascular diseases, with limited side effects. ..
  56. Pericytes, pathological angiogenesis and diabetic retinopathy
    Ira M Herman; Fiscal Year: 2010
    ....
  57. LOCATION OF PORE SYSTEMS IN CAPILLARY WALLS
    George Palade; Fiscal Year: 2000
    ..V. In specific aim # 5, the characterization of fenestrated endothelia from diaphragmatic capillaries, e.g., peritubular capillaries will be carried out by utilizing the techniques described in above specific aims. ..
  58. Structure-Based Design of Eph Receptor Antagonists
    Longqin Hu; Fiscal Year: 2005
    ..abstract_text> ..
  59. Placental growth factor in skin angiogenesis
    Michael Detmar; Fiscal Year: 2001
    ..Understanding the molecular mechanisms that control skin and tumor angiogenesis will be the basis for the development of novel therapeutic approaches to treat inflammatory skin diseases and skin cancer. ..
  60. REGULATION OF ANGIOGENESIS BY PAI1
    Daniel Lawrence; Fiscal Year: 2001
    ..Finally, the role of PAI-1 in tumor angiogenesis will also be analyzed in congenic and xenograft models. ..
  61. Bronchial Angiogenesis in the Ischemic Lung
    Adlah Sukkar; Fiscal Year: 2007
    ..Thus, gaining knowledge of this process and its' consequences is highly relevant. [unreadable] [unreadable] [unreadable] [unreadable]..
  62. CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO
    Bela Anand Apte; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  63. Vascular Remodeling and Effects of Angiogenic Inhibition
    Patricia Parsons Wingerter; Fiscal Year: 2006
    ..The CAM continues to serve as a convenient testbed for ongoing development of fractal methods and for examination of effects of human regulators on angiogenesis and vascular remodeling. ..
  64. Vacsular Remodeling and Effects of Angiogenic Inhibition in Diabetic Retinopathy
    Peter Kaiser; Fiscal Year: 2006
    ..The CAM continues to serve as a convenient testbed for ongoing development of fractal methods and for examination of effects of human regulators on angiogenesis and vascular remodeling. ..
  65. The Angiopoietins in Vascular Maintenance and Remodeling
    Christopher Kontos; Fiscal Year: 2005
    ..Moreover, these studies may lead to the identification of novel therapeutic targets in a variety of vascular diseases. ..
  66. Tie2 Regulation and Role in Pathological Angiogenesis
    CLARENCE FINDLEY; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  67. A Lymphatic-specific fluorescent transgenic model
    Young Kwon Hong; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  68. Role of integrin in postnatal & pathologic angiogenesis
    SOTIRIS NIKOLOPOULOS; Fiscal Year: 2005
    ..The proposed research would be beneficial towards the understanding of both alpha6beta4 integrin function as well as the molecular basis of postnatal and pathological angiogenesis. ..